A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy. Issue 29 (17th June 2019) - Ding, Feng
Abstract : A novel NIR-II theranostic nanoprobe, PSY (∼110 nm), was concisely developed, which demonstrated excellent photostability, high tumor uptake, superior S/N ratios and more efficient cancer treatment with minimal side effects than cisplatin. Abstract : The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000–1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe, PSY (size ∼110 nm), by incorporating organoplatinum(ii ) metallacyclesP1 and an organic NIR-II molecular dye, SY1030, into the FDA-approved polymer Pluronic F127. Preliminary in vitro and in vivo studies suggest thatPSY is capable of being internalized into glioma U87MG-cells with no significant internalization in non-cancerous tissues. In addition, it shows excellent photostability and minimal background for real-time monitoring the process of therapy in the NIR-II region. Furthermore, in U87MG xenografts and orthotopic breast tumor, PSY demonstrat significantly improved anticancer efficacy compared to a clinically approved Pt(ii )-based anticancer drug, cisplatin. The engineered nano-cocktailPSY offers a simple strategy for delivering the organoplatinum(ii ) macrocycleP1 and NIR-II fluorophoreSY1030 as a cocktail of diagnostic and therapeutic functions and highlights its promising capacity for future cancer treatment.